Voyager Therapeutics Inc (VYGR) - News Archive

The Frontier of Genetic Medicine: Voyager s Next-Generation CNS Capsids and the Future of Neurological Therapies In the rapidly evolving field of genetic medicine, innovative breakthroughs are frequently redefining poss...

Voyager Therapeutics, a prominent company in the field of gene therapy, has announced the selection of VY1706 as their lead candidate for a promising tau silencing gene therapy aimed at treating Alzheimer s disease. Thi...

Voyager Therapeutics, Inc. has made significant strides in recent months, underscoring its commitment to advancing gene therapy through strategic partnerships and notable financial improvements. This article delves into...

Voyager Therapeutics Enters into Employment Agreement with New Hires, Impacting Shareholders LEXINGTON, Mass. Aug. 29, 2024 - Voyager Therapeutics, Inc. (Nasdaq: VYGR), a pioneering biotechnology company focused on adva...

Reversing the Tide of Alzheimer s: Voyager Therapeutics Initiates Promising Phase 1a Trial with VY-TAU01, a Novel Anti-Tau AntibodyLEXINGTON, Mass., May 16, 2024 - In the relentless pursuit of innovative neurogenetic tr...

Voyager also presented data on its Tau silencing gene therapy program intended for Alzheimer s disease, which is advancing into later stages of research. Voyager s lead antibody, VY-TAU01, targets pathological tau and h...

In a recent press release, Voyager Therapeutics, a pioneering biotechnology company dedicated to advancing neurogenetic medicines, announced the grant of non-qualified stock options and restricted stock units to Dr. Tob...

Friedreich s ataxia (FA) is a debilitating genetic neurodegenerative disorder that affects approximately 1 in 50,000 individuals worldwide. Characterized by progressive loss of coordination, muscle weakness, and impaire...

Alzheimer s disease (AD) is a neurodegenerative disorder characterized by the accumulation of abnormal tau protein in the brain. Voyager Therapeutics, a leading biotechnology company focused on developing gene therapies...

Voyager Therapeutics Successful Public Offering Boosts Shareholder ConfidenceLEXINGTON, Mass., Jan. 04, 2024 - Voyager Therapeutics, a pioneering biotechnology company focused on advancing neurogenetic medicines, announ...

Voyager Therapeutics Announces Commencement of Public Offering, Empowering Shareholders LEXINGTON, Mass., Jan. 04, 2024 - Voyager Therapeutics, Inc. (Nasdaq: VYGR), a leading biotechnology company dedicated to advancing...

Gene therapies have emerged as a promising frontier in the healthcare industry, offering potential cures for previously untreatable diseases. Voyager Therapeutics, a renowned clinical-stage gene therapy company, has rec...

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Sept. 07, 2023 - Voyager Therapeutics, Inc. (Nasdaq: VYGR), a renowned biotechnology company dedicated to breakthrou...